Novartis loses Indian patent fight in landmark ruling

Novartis loses Indian patent fight in landmark ruling

India’s top court denied Monday a patent request by Swiss drug giant Novartis for its cancer drug Glivec in a landmark decision seen as crucial for India’s status as a global source of cheap medicines.

The Supreme Court ruled that the compound for which Novartis was seeking a patent “did not satisfy the test of novelty or inventiveness” required by Indian law.


Comment count on this article reflects comments made on Breitbart.com and Facebook. Visit Breitbart's Facebook Page.

Like Breitbart on Facebook

FROM THE HOMEPAGE